MANAGEMENT OF RHEUMATOID ARTHRITIS IN ELDERLY PATIENTS

D. Cansu, C. Korkmaz
{"title":"MANAGEMENT OF RHEUMATOID ARTHRITIS IN ELDERLY PATIENTS","authors":"D. Cansu, C. Korkmaz","doi":"10.56543/aaeeu.2023.2.3.08","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic inflammatory disease that is characterized by polyarthritis, progresses with joint damage, and may involve extra-articular tissue. Although RA can develop at any age, its prevalence increases with age. The number of elderly RA patients is gradually increasing due to both the increase in the frequency of late-onset (age 65 and over) RA (LORA) patients and the increased life expectancy. RA is characterized by inappropriately accelerated immune aging that occurs in the early period and is independent of disease duration. Aging can affect both the onset and the clinical phenotype of RA. Moreover, one of the most challenging issues for specialists is the treatment of RA in elderly patients. Targeted treatment of RA in elderly patients is inadequate or not optimally administered due to patients’ pre-existing comorbidities, polypharmacy, physicians’ concerns about possible drug side effects, and the lack of specific treatment guidelines for elderly RA patients. Elderly RA patients have been rarely and sometimes not even included in randomized controlled trials due to both age and comorbidities. Nevertheless, evidence for the safety and efficacy of specific RA treatments in the elderly population is gradually increasing. In elderly patients with RA, disease activity, all the comorbidities of the patient, and possible side effects of the drugs should be taken into consideration when making treatment decisions, and the treatment target should be individualized. In this review, the epidemiology of elderly RA patients, their comorbidities, briefly immune aging in RA, and the medical treatment approach in elderly RA will be discussed in light of studies.","PeriodicalId":480039,"journal":{"name":"Anti-Aging Eastern Europe","volume":"13 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Aging Eastern Europe","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.56543/aaeeu.2023.2.3.08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that is characterized by polyarthritis, progresses with joint damage, and may involve extra-articular tissue. Although RA can develop at any age, its prevalence increases with age. The number of elderly RA patients is gradually increasing due to both the increase in the frequency of late-onset (age 65 and over) RA (LORA) patients and the increased life expectancy. RA is characterized by inappropriately accelerated immune aging that occurs in the early period and is independent of disease duration. Aging can affect both the onset and the clinical phenotype of RA. Moreover, one of the most challenging issues for specialists is the treatment of RA in elderly patients. Targeted treatment of RA in elderly patients is inadequate or not optimally administered due to patients’ pre-existing comorbidities, polypharmacy, physicians’ concerns about possible drug side effects, and the lack of specific treatment guidelines for elderly RA patients. Elderly RA patients have been rarely and sometimes not even included in randomized controlled trials due to both age and comorbidities. Nevertheless, evidence for the safety and efficacy of specific RA treatments in the elderly population is gradually increasing. In elderly patients with RA, disease activity, all the comorbidities of the patient, and possible side effects of the drugs should be taken into consideration when making treatment decisions, and the treatment target should be individualized. In this review, the epidemiology of elderly RA patients, their comorbidities, briefly immune aging in RA, and the medical treatment approach in elderly RA will be discussed in light of studies.
对老年类风湿关节炎患者的管理
类风湿性关节炎(RA)是一种慢性炎症性疾病,以多发性关节炎为特征,随着关节损伤进展,并可能累及关节外组织。尽管RA可以在任何年龄发生,但其患病率随着年龄的增长而增加。由于晚发性(65岁及以上)RA (LORA)患者频率的增加和预期寿命的延长,老年RA患者的数量正在逐渐增加。RA的特点是免疫老化不适当加速,发生在早期,与疾病持续时间无关。衰老可以影响RA的发病和临床表型。此外,对于专家来说,最具挑战性的问题之一是老年RA患者的治疗。由于患者已有的合并症、多种用药、医生对可能的药物副作用的担忧以及缺乏针对老年RA患者的具体治疗指南,老年RA患者的靶向治疗不充分或不理想。由于年龄和合并症的原因,老年RA患者很少被纳入随机对照试验,有时甚至没有纳入。然而,老年人群中特定类风湿性关节炎治疗的安全性和有效性的证据正在逐渐增加。老年RA患者在进行治疗决策时,应综合考虑疾病活动性、患者的所有合并症以及药物可能产生的副作用,个体化治疗。本文将结合相关研究,就老年RA的流行病学、合并症、免疫老化及老年RA的治疗方法进行综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信